Criteria to achieve safe antimicrobial intravenous-to-oral switch in hospitalised adult populations: a systematic rapid review

Author:

Harvey Eleanor JORCID,McLeod MonseyORCID,De Brún Caroline,Ashiru-Oredope DianeORCID

Abstract

ObjectivesThis rapid review aimed to assess and collate intravenous-to-oral switch (IVOS) criteria from the literature to achieve safe and effective antimicrobial IVOS in the hospital inpatient adult population.DesignThe rapid review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.Data sourcesOVID Embase and Medline databases.Eligibility criteriaArticles of adult populations published globally between 2017 and 2021 were included.Data extraction and synthesisAn Excel spreadsheet was designed with specific column headings. IVOS criteria from UK hospital IVOS policies informed the framework synthesis.ResultsIVOS criteria from 45/164 (27%) local IVOS policies were categorised into a five-section framework: (1) timing of IV antimicrobial review, (2) clinical signs and symptoms, (3) infection markers, (4) enteral route and (5) infection exclusions. The literature search identified 477 papers, of which 16 were included. The most common timing for review was 48–72 hours from initiation of intravenous antimicrobial (n=5, 30%). Nine studies (56%) stated clinical signs and symptoms must be improving. Temperature was the most frequently mentioned infection marker (n=14, 88%). Endocarditis had the highest mention as an infection exclusion (n=12, 75%). Overall, 33 IVOS criteria were identified to go forward into the Delphi process.ConclusionThrough the rapid review, 33 IVOS criteria were collated and presented within five distinct and comprehensive sections. The literature highlighted the possibility of reviewing IVOS before 48–72 hours and of presenting heart rate, blood pressure and respiratory rate as a combination early warning score criterion. The criteria identified can serve as a starting point of IVOS criteria review for any institution globally, as no country or region limits were applied. Further research is required to achieve consensus on IVOS criteria from healthcare professionals that manage patients with infections.PROSPERO registration numberCRD42022320343.

Funder

UK Health Security Agency

Publisher

BMJ

Subject

General Medicine

Reference52 articles.

1. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis;Murray;The Lancet,2022

2. O’Neill J . Tackling drug-resistant Infectios globally: final report and recommendations. 2016. Available: https://apo.org.au/sites/default/files/resource-files/2016-05/apo-nid63983.pdf [Accessed Aug 2022].

3. European centre for disease prevention and control. summary of the latest data on antibiotic consumption in the European Union. 2017. Available: https://www.ecdc.europa.eu/sites/default/files/documents/Final_2017_EAAD_ESAC-Net_Summary-edited%20-%20FINALwith%20erratum.pdf [Accessed Aug 2022].

4. UK health security agency . English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report. 2021. Available: https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report [Accessed Aug 2022].

5. What is antimicrobial stewardship?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3